NCT02919917View on ClinicalTrials.gov

Treatment of Post-SCI Hypotension

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

September 1, 2021

Study Completion Date

September 1, 2021

Conditions
Spinal Cord InjuryAutonomic DysreflexiaOrthostatic HypotensionBaroreceptor IntegritySympathetic IntegrityVagal IntegrityHypotensionCerebral Blood FlowBlood PressureVenous Occlusion Plethysmography
Interventions
DRUG

Midodrine Hydrochloride

Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d

DRUG

Midodrine Hydrochloride

Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d

Trial Locations (2)

10029

Mount Sinai School of Medicine, New York

10468

VA Medical Center, Bronx, The Bronx

All Listed Sponsors
collaborator

Icahn School of Medicine at Mount Sinai

OTHER

lead

James J. Peters Veterans Affairs Medical Center

FED

NCT02919917 - Treatment of Post-SCI Hypotension | Biotech Hunter | Biotech Hunter